CRSP vs. KRYS, IMVT, HALO, IBRX, RVMD, EXEL, SWTX, IOVA, DNLI, and IMCR
Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Krystal Biotech (KRYS), Immunovant (IMVT), Halozyme Therapeutics (HALO), ImmunityBio (IBRX), Revolution Medicines (RVMD), Exelixis (EXEL), SpringWorks Therapeutics (SWTX), Iovance Biotherapeutics (IOVA), Denali Therapeutics (DNLI), and Immunocore (IMCR). These companies are all part of the "biological products, except diagnostic" industry.
Krystal Biotech (NASDAQ:KRYS) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.
CRISPR Therapeutics' return on equity of -5.74% beat Krystal Biotech's return on equity.
86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 14.1% of Krystal Biotech shares are held by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
CRISPR Therapeutics received 181 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 66.83% of users gave Krystal Biotech an outperform vote while only 65.38% of users gave CRISPR Therapeutics an outperform vote.
Krystal Biotech has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
In the previous week, CRISPR Therapeutics had 21 more articles in the media than Krystal Biotech. MarketBeat recorded 27 mentions for CRISPR Therapeutics and 6 mentions for Krystal Biotech. CRISPR Therapeutics' average media sentiment score of 0.75 beat Krystal Biotech's score of 0.20 indicating that Krystal Biotech is being referred to more favorably in the media.
Krystal Biotech currently has a consensus price target of $171.00, indicating a potential upside of 4.20%. CRISPR Therapeutics has a consensus price target of $73.93, indicating a potential upside of 31.50%. Given Krystal Biotech's higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than Krystal Biotech.
Krystal Biotech has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.
Summary
Krystal Biotech beats CRISPR Therapeutics on 12 of the 17 factors compared between the two stocks.
Get CRISPR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CRISPR Therapeutics Competitors List
Related Companies and Tools
